Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday

Edwards Lifesciences (NYSE:EW - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect Edwards Lifesciences to post earnings of $0.62 per share and revenue of $1.49 billion for the quarter. Edwards Lifesciences has set its FY 2025 guidance at 2.400-2.500 EPS and its Q2 2025 guidance at 0.590-0.650 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.66 EPS. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.17 during midday trading on Thursday, reaching $75.98. 1,696,029 shares of the stock were exchanged, compared to its average volume of 5,254,767. The firm has a market cap of $44.57 billion, a price-to-earnings ratio of 10.83, a PEG ratio of 3.86 and a beta of 1.11. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $76.42 and a two-hundred day simple moving average of $73.41. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $88.61.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Evercore ISI upped their price target on Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Mizuho upped their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock an "outperform" rating in a research report on Wednesday. Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Finally, Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $81.00.

Insider Buying and Selling

In related news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president directly owned 33,496 shares of the company's stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,848 shares of company stock valued at $2,314,488. 1.29% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Edwards Lifesciences stock. Brighton Jones LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,587 shares of the medical research company's stock, valued at approximately $266,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.